Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment

Titre traduit de la contribution: Biomarqueurs prédictifs de l'efficacité des inhibiteurs de checkpoint immunitaire dans le traitement des cancers

Michaël Duruisseaux, Cécile Lize-Dufranc, Céline Badoual, Frédéric Bibeau

Résultats de recherche: Contribution à un journalBrève enquêteRevue par des pairs

3 Citations (Scopus)

Résumé

The remarkable efficacy of PD-1/PD-L1 and CTLA4 immune checkpoint inhibitors has led to numerous approvals in melanoma, non-small cell lung cancer, kidney cancer and several other cancers. Nevertheless, a response is observed in a variable proportion of patients, emphasizing the need for predictive biomarkers of efficacy of immune checkpoint inhibitors effectiveness. Several predictive biomarkers of efficacy are of interest: companion tests such PD-L1 immunohistochemistry, the mutational load, the immune status of the tumor and its molecular profile. They do not allow a perfect selection of the patients, but standardization procedures for certain techniques are ongoing. Moreover the emergence of new approaches, such as the multiplex in situ techniques and the microbiote analysis, may offer the opportunity to better select patients who really benefit from immunotherapy. The goal of this article is to discuss available and promising predictive biomarkers of efficacy for immunotherapy strategies.

Titre traduit de la contributionBiomarqueurs prédictifs de l'efficacité des inhibiteurs de checkpoint immunitaire dans le traitement des cancers
langue originaleAnglais
Pages (de - à)46-54
Nombre de pages9
journalAnnales de Pathologie
Volume37
Numéro de publication1
Les DOIs
étatPublié - 1 févr. 2017
Modification externeOui

Contient cette citation